Product Description
Mechanisms of Action: OPR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Russia
Approved Indications: None
Known Adverse Events: None
Company: R-Pharm
Company Location: Europe
Company Founding Year: 2001
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Alcoholism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03663374 |
CN07006005 | P3 |
Completed |
Alcoholism |
2016-04-16 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|